Compatibility «Ritonavir-100» and «Interfast»
Between «Ritonavir-100» and «Interfast» found 25 dangerous and 40 negative interactions, joint admission is not recommended without consulting a doctor.
Interaction tableCompare |
Interfast |
✘Ritonavir-100 [Ritonavir] Analogs | |
✘Interfast [Saquinavir] Analogs |
-
Interactions Ritonavir-100 with Interfast
-
Dangerous interactions
The combined use of saquinavir, ritonavir and rifampicin is not recommended due to the risk of severe hepatotoxicity (increased levels of hepatic transaminases). Taking into account the results obtained when using saquinavir in combination with ritonavir in healthy volunteers with respect to dose-dependent prolongation of QT and PR intervals (see sections 'Contraindications', 'Special instructions'), additive effects with respect to prolongation of QT and PR intervals may occur when using drugs of the following classes: antiarrhythmic agents of class IA or III, neuroleptics, tricyclic antidepressants, phosphodiesterase inhibitors of type 5 (IFDE‑5), certain antibacterial and antihistamines, as well as other medications (see below). Thus, co-administration of saquinavir in combination with ritonavir and the listed drugs should be avoided, if other alternative therapeutic options are available. Drugs that simultaneously have pharmacokinetic interaction with saquinavir in combination with ritonavir and the ability to lengthen the QT and PR intervals are strictly contraindicated. In some cases, the simultaneous use of saquinavir and ritonavir led to the development of severe adverse events of ketoacidosis and liver disorders, especially in patients with a history of liver disease. These antiarrhythmic agents are contraindicated for the combined use of saquinavir in combination with ritonavir due to the possible development of life-threatening arrhythmias. Trazodone is contraindicated for use with saquinavir in combination with ritonavir due to the possible development of life-threatening arrhythmias. The combined use of colchicine and saquinavir in combination with ritonavir is not recommended due to a possible increase in colchicine toxicity (neuromuscular disorders, in particular rhabdomyolysis), especially in patients with impaired liver and kidney function. Simultaneous use of saquinavir in combination with ritonavir is contraindicated due to the possible development of life-threatening arrhythmias. Simultaneous use of fusidic acid and saquinavir/ritonavir is not recommended due to the possible increase in toxicity of both drugs. The simultaneous use of saquinavir/ritonavir has not been studied. The use of rifampicin is contraindicated in patients taking saquinavir in combination with ritonavir as part of antiretroviral therapy, due to the possibility of severe hepatocellular toxicity. Oral administration of midazolam in combination with saquinavir / ritonavir is contraindicated due to the possible development of prolonged sedation. Concomitant use of saquinavir in combination with ritonavir is contraindicated due to the risk of prolonged/excessive sedation and respiratory depression. The simultaneous use of these drugs with saquinavir in combination with ritonavir is contraindicated, due to the possibility of acute toxicity. The use of simvastatin and lovastatin in combination with saquinavir /ritonavir is contraindicated. Concomitant use with saquinavir in combination with ritonavir is contraindicated due to the possible development of life-threatening arrhythmias. Concomitant use with saquinavir/ritonavir has not been studied. Although no special studies have been conducted, concomitant administration of saquinavir/ritonavir and other drugs that are substrates of CYP3A4 isoenzymes may increase plasma concentrations of these drugs. Cisapride is contraindicated in patients taking saquinavir in combination with ritonavir, due to the possible occurrence of life-threatening arrhythmias. Pimozide is contraindicated in patients taking saquinavir in combination with ritonavir, due to the possible development of life-threatening arrhythmias. The combined use of alfuzosin and saquinavir in combination with ritonavir is contraindicated due to the possible development of arterial hypotension. Terfenadine is contraindicated in patients taking saquinavir in combination with ritonavir, due to the possible development of life-threatening arrhythmias. Due to the high probability of a similar interaction, saquinavir in combination with ritonavir should also not be prescribed together with astemizole. Although no special studies have been conducted, concomitant administration of saquinavir / ritonavir and other drugs that are substrates of the CYP3A4 isoenzyme may increase plasma concentrations of these drugs, therefore, taking such combinations is contraindicated due to the possible development of life-threatening arrhythmias (see sections 'Contraindications' and 'Special instructions'). -
Negative interactions
When ritonavir is co-administered with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir and tipranavir), full information on the appointment of a specific protease inhibitor, including important information on drug interactions, should be read. Detailed information on the combined use of saquinavir and ritonavir can be found in the instructions for the medical use of saquinavir. Increases (mutually) AUC and max'>Cmax ritonavir, nevirapine, indinavir, nelfinavir, clarithromycin, terfenadine. Information on the use of saquinavir in combination with ritonavir (enhanced mode) is limited. The results obtained during studies on the use of saquinavir in a non-amplified mode may not fully reflect the effects of using saquinavir in combination with ritonavir. Ritonavir, as a potent inhibitor of the CYP3A4 isoenzyme and P‑glycoprotein, may affect the pharmacokinetics of other drugs. When prescribing combination therapy, possible interactions with ritonavir should be considered. Interaction with saquinavir /ritonavir has not been studied. The interaction of saquinavir/ritonavir has not been studied. Taking low doses of ritonavir leads to an increase in the concentration of indinavir. In patients already taking ritonavir as part of antiretroviral therapy, additional ritonavir is not required. In HIV-infected patients, the use of saquinavir (film-coated tablets) or saquinavir (soft capsules) in combination with ritonavir at doses of 1000/100 mg 2 times a day led to a daily systemic exposure of saquinavir similar or greater than that when using saquinavir at a dose of 1200 mg 3 times a day (soft capsules). The use of higher doses of ritonavir may lead to an increase in the incidence of adverse events. Simultaneous use of tipranavir, enhanced with small doses of ritonavir, with saquinavir /ritonavir is not recommended, since the clinical significance of a decrease in Cmin. With the combined use of saquinavir / ritonavir, it is possible to increase the concentration of bepridil, lidocaine (with systemic use), quinidine, amiodarone, flecainide, propafenone. Concomitant use of saquinavir / ritonavir with drugs primarily metabolized by the CYP3A4 isoenzyme may lead to an increase in the concentration of such drugs in blood plasma. Dofetilide is contraindicated for the combined use of saquinavir/ ritonavir due to the possible development of life-threatening arrhythmias. Interaction with saquinavir/ritonavir has not been studied. The combined use of saquinavir and ritonavir is contraindicated due to the possible development of life-threatening arrhythmias. The combined use of saquinavir / ritonavir is contraindicated due to the possible development of life-threatening arrhythmias. Simultaneous administration of trazodone and saquinavir in combination with ritonavir may lead to an increase in plasma concentrations of trazodone. With simultaneous use of trazodone and ritonavir, adverse reactions such as nausea, dizziness, hypotension and fainting were observed. The combined use of colchicine and saquinavir/ritonavir may cause an increase in the concentration of colchicine in blood plasma due to inhibition of P‑glycoprotein and/or CYP3A4 isoenzyme due to HIV protease inhibitors. The interaction between saquinavir in combination with ritonavir and clarithromycin has not been studied. Concomitant use with saquinavir and ritonavir is contraindicated due to the possible development of life-threatening arrhythmias. The interaction between saquinavir in combination with ritonavir and erythromycin has not been studied. The simultaneous use of these drugs may cause an increase in the plasma concentration of fusidic acid and saquinavir /ritonavir. The interaction between saquinavir/ritonavir and itraconazole has not been studied. Information on the combined use of saquinavir, ritonavir and efavirenz is limited. The interaction between saquinavir/ritonavir and dexamethasone has not been studied. Systemic exposure of fluticasone and budesonide was observed in the case of an inhalation or intranasal route of administration of one of the drugs with low doses of ritonavir. With simultaneous use of saquinavir in combination with ritonavir and bosentan, it is possible to increase the concentration of bosentan and decrease the concentration of saquinavir / ritonavir in plasma. In the case of simultaneous use of saquinavir / ritonavir and bosentan, the patient's tolerance to bosentan should be monitored. A significant increase in digoxin concentration is possible with the simultaneous use of saquinavir/ritonavir in patients already receiving digoxin therapy. The interaction between saquinavir in combination with ritonavir and ranitidine has not been studied. With the simultaneous use of salmeterol and saquinavir / ritonavir, it is possible to increase the concentration of salmeterol in plasma. In clinical studies, with the simultaneous use of ketoconazole (a powerful inhibitor of the CYP3A4 isoenzyme) and saquinavir in combination with ritonavir, there was no increase in the pharmacokinetic exposure of saquinavir. Ritonavir may have an effect on the pharmacokinetics of other drugs, since it is itself a powerful inhibitor of the CYP3A4 isoenzyme and P‑glycoprotein, as well as an inducer of the enzyme of some cytochrome P450 isoenzymes. Saquinavir and Ritonavir belong to the same pharmaceutical group: Drugs for the treatment of HIV infection. Saquinavir and Ritonavir belong to the same pharmaceutical group: HIV protease inhibitors. -
No interactions
There is no clinical data on the use of atazanavir in combination with saquinavir /ritonavir 1000/100 mg 2 times a day. No dose adjustment is required for saquinavir/ritonavir. The effect on the concentration of saquinavir and ritonavir has not been measured and is not expected. No dose adjustment of saquinavir/ritonavir is required. Concomitant administration of saquinavir and nefazodone in combination with ritonavir has not been studied. When using ketoconazole at a dose of less than 200 mg, dose adjustment of saquinavir / ritonavir is not required. There are no data on simultaneous administration of saquinavir in combination with ritonavir and intravenous administration of midazolam. Concomitant use of saquinavir/ritonavir and fluticasone (or other glucocorticosteroids) is not recommended. Interactions with protease inhibitors, including ritonavir, are not expected. There are no data on the simultaneous use of saquinavir in combination with ritonavir and other proton pump inhibitors. The use of saquinavir in combination with ritonavir simultaneously with omeprazole or other proton pump inhibitors is not recommended. The simultaneous use of saquinavir / ritonavir with these drugs has not been studied. -
Positive interactions
It is possible to develop an additive effect with respect to prolongation of QT and/or PR intervals when using saquinavir in combination with ritonavir. The recommended dose of rifabutin when used in combination with saquinavir and ritonavir is 150 mg every other day. With the simultaneous use of saquinavir / ritonavir, an increase in the concentration of benzodiazepines is possible. With simultaneous use with saquinavir / ritonavir, it is possible to increase the exposure of ergot alkaloids. It is possible to increase the concentration of quetiapine when used concomitantly with saquinavir / ritonavir. -
Unclear interactions
HIV-1 protease inhibitor saquinavir. Saquinavir. It is not recommended to combine saquinavir and ritonavir with other drugs that have a known prolonging effect on the QT and PR intervals. (saquinavir/ritonavir 1600 mg/100 mg 4 times a day for 2 weeks,. (saquinavir/ritonavir 1000/100 mg 2 times a day,. (saquinavir/ritonavir 1600/200 mg 1 time per day or. saquinavir/ritonavir 1000/100 mg 2 times a day (n = 32). saquinavir/ritonavir 1200/100 mg 1 time per day). (saquinavir/ritonavir 1600/100 mg 1 time per day). The AUC of ritonavir is 41%. Cmax ritonavir ↑ 34%. (saquinavir/ritonavir 1000/100 mg 2 times a day in combination with two or three nucleoside reverse transcriptase inhibitors in 32 HIV-infected patients). (saquinavir 1000 mg 2 times a day and a fixed combination of lopinavir/ritonavir 400/100 mg 2 times a day in 45 HIV-infected patients). Ritonavir. (saquinavir/ritonavir 1000/100 mg 2 times a day). The use of saquinavir in combination with ritonavir and nelfinavir is not recommended. saquinavir 1000 mg 2 times a day and ritonavir 100 mg 2 times a day. (saquinavir/ritonavir 1000 mg/100 mg 2 times a day,. (saquinavir/ritonavir). Saquinavir/ritonavir may increase the concentration of tricyclic antidepressants. The AUC of ritonavir is ↔. Cmax ritonavir. AUC0-12 ritonavir. (ritonavir 100 mg 2 times a day). A single dose of 0.5 mg after two weeks of taking saquinavir in combination with ritonavir (1000/100 mg 2 times a day) in 16 healthy volunteers in a cross-sectional study. (saquinavir/ritonavir 1000/100 mg in 8 healthy volunteers 2 times a day).
-
Dangerous interactions
Decoding the colors of interactions and contraindications
Dangerous | — | a pronounced negative interaction or contraindication. |
Negative | — | negative interaction or side effect that may reduce effectiveness. |
Positive | — | the interaction can SOMETIMES be used as a positive (often a dose adjustment is needed), or it is an indication of the drug. |
No | — | the drugs do NOT interact, which is separately indicated in the instructions. |
Unclear | — | the system failed to pre-assess the danger. |
Video instruction
Additional information
- Kiberis checks interactions and evaluates drug compatibility online right in the instructions thanks to the latest artificial intelligence technologies. The accuracy of finding is more than 95%, the accuracy of the hazard assessment is more than 80%. The online medical service takes into account all the drug groups of the selected drugs and all their components. And since the database contains 25,000 drugs with detailed instructions, not every pharmacologist can compete with our artificial intelligence. List of popular interactions.
- Why do I need to
- Avoid dangerous prescriptions for your patients.
- Check the contraindications.
- Evaluate the safety of therapy in the treatment of children.
- See the compatibility of drugs with alcohol (enter it as a drug).
- Point the doctor to the found interaction - you may need to adjust the therapy.
- The use of information about interactions is only possible as an introduction. This information should not be used to adjust therapy without consulting a specialist.
- The article is written: artificial intelligence Kiberis
- Sources: official instructions for medicines and their active substances, as well as inter-group interactions described in medical studies and textbooks.
- Total analyzed: 169,972,605 possible combinations of drugs and their components were found 412,508 interacting combinations.
- Medicine section: Standard evidence-based medicine
- The date of the last update of the interaction database: 2024-04-11
Category - medicine